Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest early-stage breast cancer Stories

2009-07-27 07:00:00

ANAHEIM, Calif., July 27 /PRNewswire/ -- Xoft, Inc. today announced that it has expanded the treatment capabilities of the Axxent(R) Electronic Brachytherapy, eBx(TM), System with the launch of a multi-center skin cancer trial to further prove the safety and feasibility for the treatment of non-melanoma skin cancers here at the 51st Annual American Association of Physicists in Medicine (AAPM) Meeting. The Company also announced that the first skin cancer patients were recently treated...

2009-06-26 02:00:00

- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer recommended for the first time that validated multigene assays, such as Oncotype DX(R), should be considered as an adjunct to...

2009-06-08 13:22:19

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.A new study from the Research on Adverse Drug Events and Reports (RADAR) pharmacovigilance program at Northwestern University Feinberg School of Medicine identified 287 unique cases of hypersensitivity reactions submitted to the FDA's Adverse Event Report System between 1997 and 2007 with 109 (38 percent) deaths in patients who received...

2009-04-20 07:00:00

- Results of International Multi-Center Study Consistent with Suite of U.S. and European Clinical Studies Evaluating Oncotype DX - REDWOOD CITY, Calif. and KYOTO, Japan, April 20 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a multi-center Japanese study demonstrating that the Oncotype DX breast cancer assay had significant prognostic value in Japanese women with estrogen receptor-positive early-stage breast cancer. Oncotype DX identified a large...

2009-03-04 07:00:00

Most Recent Indication Expands Treatment Platform to Allow Axxent(R) System to Deliver Surface Brachytherapy, Including Intraoperative Radiation Therapy (IORT) SUNNYVALE, Calif., March 4 /PRNewswire/ -- Xoft, Inc., today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) for a skin and surface treatment applicator for use with the Axxent(R) Electronic Brachytherapy (eBx) System to deliver surface brachytherapy, including Intraoperative Radiation...

2008-12-05 07:00:00

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Center. Two of the studies analyze Oncotype DX(R), the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of...

2008-09-30 09:01:00

EVERGREEN PARK, Ill., Sept. 30 /PRNewswire/ -- The Comprehensive Breast Health Center at Little Company of Mary Hospital announced a breakthrough procedure that delivers a complete dose of radiation therapy in the operating room at the time of surgery (lumpectomy) for patients with early stage breast cancer. The first treatment was performed on a breast cancer patient as part of a clinical trial at the Hospital. Marianne Howley, of Palos Park, underwent the procedure on September 3rd...

2008-09-23 09:01:09

Clinical experience with the SAVI(TM) breast brachytherapy applicator has been outstanding, according to a scientific poster presented at the 2008 Breast Cancer Symposium, Sept. 5-7, 2008 in Washington, D.C. The retrospective study evaluated the first 102 patients to undergo therapy with the device, making it the largest clinical review of the SAVI applicator to date. Researchers concluded that SAVI expands the number of women with early-stage breast cancer who are eligible for breast...

2008-09-22 12:00:38

BOSTON, Sept. 22 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy (eBx) System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, will showcase early clinical experience with its growing suite of oncology treatment technologies here at the 49th American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, September 21-24. Developed for the treatment of early...

2008-09-18 09:00:49

BOSTON, Sept. 18 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System (eBx), which delivers non-radioactive, X-ray-based radiation treatment directly to cancer sites with minimal exposure to surrounding healthy tissue, announced that it will launch the Axxent Xpress(TM) Mobile Electronic Brachytherapy Vehicles to expand and improve access to critical radiation therapy. The announcement was made in advance of the 49th American Society for Therapeutic...